Pfiz­er has agreed to pay $290,000 to set­tle al­le­ga­tions of ques­tion­able co­pay coupon prac­tices in Ari­zona, Col­orado, Kansas, and Ver­mont from 2014 to 2018.

While the com­pa­ny has not ad­mit­ted any wrong­do­ing as part of the set­tle­ment, Pfiz­er has agreed to is­sue resti­tu­tion checks to about 5,000 con­sumers.

A Pfiz­er spokesper­son said the com­pa­ny has “en­hanced its co-pay coupons to al­le­vi­ate the con­cerns raised by states and agreed to a $30,000 pay­ment to each.”

Ac­cord­ing to Col­orado At­tor­ney Gen­er­al Phil Weis­er, Pfiz­er will re­fund about $107,000 to ap­prox­i­mate­ly 1,500 Col­orado con­sumers af­ter it failed to hon­or coupons for three drugs, in­clud­ing Es­tring, which is a ring used af­ter menopause that con­tin­u­ous­ly re­leas­es an es­tro­gen; AD­HD drug Quil­li­vant; and the pain drug Flec­tor Patch.

“While many Con­sumers paid less than or equal to the ‘PAY NO MORE THAN’ amount that ap­peared on the rel­e­vant Pfiz­er Co­pay­ment Coupons, hun­dreds of Con­sumers paid more than the ‘PAY NO MORE THAN’ amount in­di­cat­ed on the Co­pay­ment Coupons,” the Col­orado set­tle­ment says.

In ear­ly 2018, Pfiz­er al­so be­gan chang­ing the text of the “PAY NO MORE THAN” coupons to say that pa­tients could “PAY AS LIT­TLE AS” an­oth­er list­ed amount.

Weis­er said the state will use its $30,000 pay­ment for the re­im­burse­ment of the state’s ac­tu­al costs and at­tor­neys’ fees, the pay­ment of resti­tu­tion, if any, and for fu­ture con­sumer fraud, con­sumer cred­it or an­titrust en­force­ment, con­sumer ed­u­ca­tion, or pub­lic wel­fare pur­pos­es.

The more than $105,000, mean­while, will be dis­trib­uted to Col­orado con­sumers in a mailed check with­in the next four months along with a let­ter ex­plain­ing the set­tle­ment. Oth­er state at­tor­neys gen­er­al did not in­di­cate how much they re­ceived as part of their set­tle­ments.

Pfiz­er in 2018 al­so agreed to pay about $700,000 to set­tle charges of mis­lead­ing peo­ple with co­pay coupons.

Two weeks ago, Biohaven hit an all-time high in weekly Nurtec prescriptions. CEO Vlad Coric attributes at least some of that success to a new interactive Twitter campaign that encourages patients to free their feed of potential migraine triggers.

Earlier this month, Biohaven in partnership with Twitter launched the #RelieveYourFeed campaign that allows users to customize their app settings based on their migraine triggers.

Over the past few months, oncologists have been talking a lot about the ASCO conference. Not surprising considering its import and the study data presented, but what may be less expected is the second most talked about topic of health equity.

That’s according to data from The Harris Poll and the new expert network the researcher is building out. While the company has been doing deep data dives into specific health issues or conditions for pharma clients, it’s now monitoring influencer networks of therapy area specialists to find out what experts are really thinking about.

Earlier this year, Novartis touted its radioligand as a major piece to counter competition in the cancer space. However, the physical production of its products has had anything but a smooth ride.

In May, Novartis had to suspend production of Lutathera and Pluvicto, its two primary radiotherapies. According to the company, this was done out of an abundance of caution as a result of potential quality issues identified in its manufacturing. The production suspension impacts the commercial and clinical trial supply of the products.

The rise of pharma environmental, social and governance (ESG) efforts in the past two years has been meteoric as investors turn their attention to sustainable funding. However, investors aren’t the only ones watching. Patients are beginning to tune into pharmas’ ESG promises too.

Patient advocacy groups familiar with ESG regard it as an important issue and want to be included in helping pharma companies set ESG policies and targets, according to a new report from PatientView. That’s quite different from what the investment community wants across a variety of Gartner’s defined financial, competitive, strategic and perception goals.